Transgenic Biosensors for Organophosphorous Poisoning and the Protective Efficacy of Defense Agents Toward an Engineered Cholinesterase Decoy

Abstract

We have successfully developed the transient transgenic Xenopus tadpole as a useful in vitro model in which to test potential defense agents (Ben Aziz-Aloya et al., 1993). We are now directing attention to development of the defense agent itself. Our goal has been to develop an antidote for organophosphorus chemical agents (OPs), based on an engineered human butyrylcholinesterase (hBuChE). Among the reasons for basing the development on hBuChE are: (1) It already offers limited protection, reacting with OPs and sparing acetylcholinesterase (hAChE) of the CNS and neuromuscular junctions. (2) As a serum enzyme, it will protect against systemic effects of OPs. (3) Variants are likely to be non-immunogenic, as there are no known autoimmune complications involving hBuChE, and the Changes we wish to introduce in the enzyme are not on exposed surfaces. (4) Natural variations of the level of hBuChE activity are well-tolerated (Neville et al., 1992). How will we recognize the ideal variant when we meet it? Our operational requirements for an improved hBuChE are that it: (1) be more sensitive to low levels of OPs, (2) react faster with OPs, (3) be reactivated faster by 2-PAN, and (4) react with a broad range of OPs.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
May 13, 1993
Accession Number
ADP008861

Entities

People

  • Hermona Soreq

Organizations

  • Hebrew University of Jerusalem

Tags

Communities of Interest

  • Biomedical

DTIC Thesaurus Topics

  • Acetylcholinesterases
  • Amino Acids
  • Antidotes
  • Biochemistry
  • Biological Sciences
  • Chemical Synthesis
  • Chemical Warfare Agents
  • Chemistry
  • Enzymes
  • Genetics
  • Immobilized Enzymes
  • Inhibitors
  • Materials
  • Medical Genetics
  • Proteins
  • Substrates

Readers

  • Immunology
  • Neurotoxicology

Technology Areas

  • Biotechnology
  • Biotechnology - Cancer Biotech